Use of antidepressants for depression in patients with Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 255-257

  Pae, Chi Un ^a,b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; MILNACIPRAN; PAROXETINE; PRAMIPEXOLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; THIOPHENES;

EID: 84873357451     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.759213     Document Type: Review

References (16)

1. Bonuccelli U, Meco G, Fabbrini G, et al. A non-Comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opin Pharmacother 2012;13:2269-80
2. Lieberman A. Depression in Parkinson's disease-A review. Acta Neurol Scand 2006;113:1-8
3. Aarsland D, Pahlhagen S, Ballard CG, et al. Depression in Parkinson disease-epidemiology, mechanisms and management. Nature reviews. Neurology 2012;8:35-47
4. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012;46:581-9
5. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010;75:1920-7
6. Black KJ, Hershey T, Koller JM, et al. A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci USA 2002;99:17113-18 (Pubitemid 36034107)
7. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65 (Pubitemid 30228411)
8. Frisina PG, Tenenbaum HR, Borod JC, et al. The effects of antidepressants in Parkinson's disease: A meta-Analysis. Int J Neurosci 2008;118:667-82 (Pubitemid 351630874)
9. Dobkin RD, Menza M, Bienfait KL, et al. Depression in Parkinson's disease: Symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatry 2011;19:222-9
10. Fernandez HH. Updates in the medical management of Parkinson disease. Cleve Clin J Med 2012;79:28-35
11. Latoo J, Mistry M, Dunne FJ. Depression in Parkinson's disease: Diagnosis and management. Br J Hosp Med (Lond) 2012;73:331-4
12. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-Treatments meta-Analysis. Lancet 2009;373:746-58
13. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-Depressive agents for depression. Cochrane Database Syst Rev 2012;10:CD006533
14. Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: A pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003;26:142-5 (Pubitemid 36676292)
15. Madhusoodanan S, Alexeenko L, Sanders R, et al. Extrapyramidal symptoms associated with antidepressants-A review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010;22:148-56
16. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-Controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-36